Vivani Medical SEC Filings

Vivani Medical, Inc. is providing an informational update by sharing an investor slide presentation in connection with its appearance at the Jefferies Global Healthcare Conference in New York. The company plans to present on June 4, 2026 at 11:05 a.m. Eastern, and the slides are available as Exhibit 99.1 and on the Investors section of its website.

The company notes that the slide deck speaks only as of its date and that Vivani has no obligation to update it, even if circumstances change. The information in this communication is being furnished under Regulation FD and is not deemed filed for liability purposes under the securities laws.

Vivani Medical’s largest shareholder, Gregg Williams, filed Amendment No. 11 to his Schedule 13D, reporting beneficial ownership of 43,218,497 shares of common stock, or 47.1% of the company’s outstanding shares. This total includes shares held through several family trusts and LLCs, as well as warrants and stock options exercisable within 60 days of May 15, 2026.

Williams, together with related entities, acquired the shares for investment purposes and is deemed to control the company due to his board role and ownership level. The filing details multiple recent and ongoing share purchases by the Gregg G. Williams 2006 Trust, including structured purchase agreements with the company at prices between $0.98 and $1.62 per share, some with closings scheduled through July 15, 2026.

Vivani Medical, Inc. director and significant shareholder Gregg Williams bought 1,587,301 shares of common stock at $1.26 per share in a private sale transaction. The footnotes state the gross amount for this transaction was $1,999,999.26.

After these transactions, Williams is reported as owning a total of 39,330,985 Vivani shares directly and indirectly. This includes 4,799,200 shares held personally and additional holdings through several trusts and LLCs over which he has voting and dispositive power.

Vivani Medical reported first quarter 2026 results, highlighting a net loss of $6.8 million compared with $6.3 million a year earlier, and ending the period with $19.7 million in cash and cash equivalents. Total assets were $42.4 million and stockholders’ equity was $19.1 million.

Operating expenses rose modestly as research and development reached $4.4 million and general and administrative expenses were $2.4 million, each up about 4% year over year. The company used $6.2 million in operating cash during the quarter and raised $9.7 million through a registered direct offering and other securities purchase agreements, contributing to an expected cash runway through the first half of 2027 while it advances its GLP‑1 implant SLIM‑1 Phase 1 trial and prepares a potential Phase 2 study.

Vivani Medical reported a net loss of $6.8 million for the quarter ended March 31, 2026, slightly higher than the $6.3 million loss a year earlier as it advanced its clinical-stage implant programs.

Research and development expenses were $4.4 million and general and administrative costs were $2.4 million, both up about 4% year over year. Cash, cash equivalents and restricted cash totaled $21.1 million, including $19.7 million of cash and cash equivalents, supported by $9.7 million of net financing inflows in the quarter from private sales and a registered direct offering.

The company estimates its current capital, plus remaining committed equity financings, can fund operations into mid‑2027, but additional capital will be needed beyond that as it continues developing its NanoPortal-based GLP‑1 implant candidates and works to separate its Cortigent neurostimulation business.

Vivani Medical, Inc. is asking stockholders at its June 24, 2026 virtual annual meeting to elect six directors, including new independent nominee August Moretti, and to approve a non-binding advisory "say-on-pay" vote on executive compensation.

Stockholders are also asked to approve an amended and restated 2022 Omnibus Incentive Plan that increases the share reserve by 11,000,000 shares to a total of 21,033,333 shares, and to ratify BPM LLP as independent registered public accounting firm for the year ending December 31, 2026. The record date is April 27, 2026, when 86,235,104 common shares were outstanding and entitled to one vote per share.

Vivani Medical, Inc. director and 10% owner Gregg Williams bought 1,587,301 shares of common stock in a private sale at $1.26 per share, under a Share Purchase Agreement dated August 11, 2025. The gross proceeds for this transaction were $1,999,999.26. After the purchase, he beneficially owns a total of 37,743,684 shares, including 4,799,200 shares held directly and additional shares held through several trusts and LLCs over which he has voting and dispositive power.

Vivani Medical, Inc. reported fourth quarter and full year 2025 results, highlighting progress on its GLP‑1 implant pipeline and funding. The company advanced NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management, supported by first-in-human LIBERATE-1 data and year-long preclinical results showing sustained semaglutide exposure and more than 20% sham-adjusted weight loss after a single implant.

Vivani plans to start a Phase 1 feasibility study of NPM-139 in Australia in mid-2026, with initial data anticipated by year-end 2026, and aims to follow with a Phase 2 study. It is also exploring a separation of neuromodulation subsidiary Cortigent into an independent, publicly traded company. For 2025, the company reported a net loss of $26,609 thousand, or $0.43 per share, on operating expenses of $27,556 thousand. Cash and cash equivalents were $16,232 thousand as of December 31, 2025, and combined cash, equivalents and commitments are expected to fund operations into mid‑2027 after raising $41 thousand in recent financings.